MaxCyte (NASDAQ:MXCT - Get Free Report) is anticipated to issue its quarterly earnings data after the market closes on Tuesday, March 11th. Analysts expect the company to announce earnings of ($0.14) per share and revenue of $7.98 million for the quarter. Individual interested in listening to the company's earnings conference call can do so using this link.
MaxCyte Stock Performance
Shares of NASDAQ MXCT remained flat at $3.51 during mid-day trading on Friday. The company had a trading volume of 774,005 shares, compared to its average volume of 590,234. The company has a market capitalization of $371.92 million, a price-to-earnings ratio of -10.32 and a beta of 1.35. The business's fifty day moving average is $4.27 and its 200 day moving average is $4.01. MaxCyte has a 52-week low of $3.16 and a 52-week high of $5.26.
About MaxCyte
(
Get Free Report)
MaxCyte, Inc, a life sciences company, discovers, develops, and commercializes next-generation cell therapies in the United States and internationally. Its products include ExPERT ATx, a static electroporation instrument for small to medium scale transfection; ExPERT STx, a flow electroporation for protein production and drug development, as well as expression of therapeutic targets for cell-based assays; ExPERT GTx, a flow electroporation for large scale transfection in therapeutic applications; and ExPERT VLx for very large volume cell-engineering.
Recommended Stories
Before you consider MaxCyte, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and MaxCyte wasn't on the list.
While MaxCyte currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Options trading isn’t just for the Wall Street elite; it’s an accessible strategy for anyone armed with the proper knowledge. Think of options as a strategic toolkit, with each tool designed for a specific financial task. Get this report to learn how options trading can help you use the market’s volatility to your advantage.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
